Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA warns beverage makers on claims, fortification

This article was originally published in The Tan Sheet

Executive Summary

FDA issues warning letters to the makers of Lipton teas and Canada Dry ginger ale for unauthorized nutrition claims. In an Aug. 23 letter, the agency warns Unilever that its Lipton Green Tea product is an unapproved new drug because its website cites studies showing people who drink tea or tea flavonoids have lower cholesterol. The tea is offered for the treatment of conditions a layperson could not diagnose or treat, FDA says, so adequate directions can't be written to ensure its safe use. The tea also includes unapproved nutrient claims, including "high in antioxidant vitamin C," "rich in naturally protective antioxidants" and "packed with flavonoid antioxidants." In an Aug. 30 letter, FDA warns Dr Pepper Snapple Group it does not consider it appropriate to fortify snack foods such as the firm's Canada Dry Sparkling Green Tea Ginger Ale, which additionally is not in compliance with guidance on antioxidant claims or "more" nutrient content claims. FDA took a similar stance toward Coca-Cola's Diet Coke Plus in 2008 (1"The Tan Sheet" Jan. 5, 2009). Both letters request responses within 15 days of receipt detailing how the company will change the labeling

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104493

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel